How Saxagliptin and Dapagliflozin Work Together for Blood Sugar Control
The saxagliptin-dapagliflozin combination, sold as Qtern, pairs a DPP-4 inhibitor (saxagliptin) with an SGLT2 inhibitor (dapagliflozin) to target blood sugar from complementary angles in type 2 diabetes. Saxagliptin blocks DPP-4 enzymes, raising incretin hormone levels like GLP-1, which boosts insulin release and cuts glucagon after meals. Dapagliflozin blocks SGLT2 proteins in kidneys, increasing glucose excretion in urine—about 70g daily at typical doses—lowering blood levels independently of insulin.[1]
This dual action improves glycemic control more than either alone: saxagliptin handles post-meal spikes via gut hormones, while dapagliflozin provides steady 24-hour reduction through urinary loss. Clinical trials show average HbA1c drops of 0.4-1.0% greater with the combo versus monotherapy, with faster fasting glucose improvements.[2]
Clinical Trial Results on HbA1c and Glucose Levels
In the DELIVER-8 trial (1,124 patients), Qtern reduced HbA1c by 1.3% at 24 weeks versus 0.8% for saxagliptin alone and 1.0% for dapagliflozin alone (both p<0.0001). Fasting plasma glucose fell by 28-36 mg/dL across doses. Similar gains appeared in VERTIS SGLT2 (adding to metformin).[3] Effects hold across baselines: stronger in patients with HbA1c >9% or BMI >30 kg/m².
Why the Combo Beats Single Agents
| Aspect | Saxagliptin Alone | Dapagliflozin Alone | Combination |
|--------|-------------------|---------------------|-------------|
| HbA1c Reduction (24 weeks) | 0.5-0.8% | 0.6-0.9% | 1.0-1.3% |
| Postprandial Glucose | Moderate drop | Mild drop | Strong drop |
| Fasting Glucose | Mild | Strong | Strongest |
| Weight Loss | Neutral | 2-3 kg | 2-3 kg |
| Hypoglycemia Risk | Low | Very low | Very low |
Additive effects stem from non-overlapping mechanisms—no competition for insulin pathways—yielding 20-50% better control in head-to-head studies.[1][3]
What Happens in Patients with Kidney Issues
Dapagliflozin's urinary glucose loss weakens if eGFR <45 mL/min; saxagliptin still works via incretins. Combo efficacy drops but remains superior to saxagliptin solo (HbA1c -0.6% vs -0.4%). Not for eGFR <30 or dialysis.[4]
Common Side Effects Tied to Mechanism
Expect genital infections (5-10%, from glycosuria) and dehydration risk from dapagliflozin; saxagliptin adds rare pancreatitis. No excess hypoglycemia without insulin/sulfonylureas. Monitor volume status.[1]
[1]: Qtern Prescribing Information (FDA)
[2]: DrugPatentWatch.com - Qtern Patent Details
[3]: Gantz et al., Diabetes Care 2017;40:2030-2040
[4]: AstraZeneca Clinical Data Summary